Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 7686 results

  1. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development [GID-TA11023] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  2. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325](review of TA677)

    In development [GID-TA11545] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  3. Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235

    In development [GID-TA11246] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221

    In development [GID-TA11183] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  5. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]

    In development [GID-TA11267] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over [ID6140]

    In development [GID-TA11062] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  9. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  10. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Awaiting development [GID-TA11338] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312

    Awaiting development [GID-TA11329] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

    In development [GID-TA10893] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

    In development [GID-NG10419] Expected publication date: 31 March 2025

    NICE guideline
    In development

  15. Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)

    In development [GID-NG10415] Expected publication date: TBC

    NICE guideline
    In development